Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Indraprastha-Medical-Corporation-Limited"

3 News Found

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
News | August 06, 2024

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
News | August 06, 2023

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
News | August 09, 2022

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr

The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.

Latest Stories

Strides acquires identified ANDAs from Nostrum Laboratories, USA

RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr

Zydus Lifesciences completes 25 years of listing on NSE

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging